STO-CSCO Joint Symposium 2017

Continuing to build on the vibrant partnership of STO and CSCO, this symposium will be featured during the 20th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) from September 26 – 30, 2017.

Translated Articles

Read translations of selected articles targeting practice issues relevant to Chinese clinicians.

Browse All Topics

The Oncologist in China

Download a 2-page pdf overview of The Oncologist’s Clinical Trial Results section information.

Video Library

Watch the latest presentations from the STO First Advisory Council: LUNG CANCER: A Grand Challenge for Public Health & Education.

Past Meetings

Welcome to 'The Oncologist' in China

Recent Translated Articles from The Oncologist

Volume 22, Number 5, May 2017

Clinical Trial Results

A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
Xiao X. Wei, Andrew C. Hsieh, Won Kim, Terence Friedlander, Amy M. Lin, Mirela Louttit, Charles J. Ryan
The Oncologist 2017; 22:503-e43; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0432

索拉非尼(BAY 43-9006)治疗卡波西肉瘤患者的Ib期研究
A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma
Thomas S. Uldrick, Priscila H. Gonçalves, Kathleen M. Wyvill, Cody J. Peer, Wendy Bernstein, Karen Aleman, Mark N. Polizzotto, David Venzon, Seth M. Steinberg, Vickie Marshall, Denise Whitby, Richard F. Little, John J. Wright, Michelle A. Rudek, William D. Figg, Robert Yarchoan
The Oncologist 2017; 22:505-e49; first published on March 24, 2017; doi:10.1634/theoncologist.2016-0486

Breast Cancer

Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor‐Positive Metastatic Breast Cancer
Virginia G. Kaklamani, William J. Gradishar
The Oncologist 2017; 22:507-517; first published on March 17, 2017; doi:10.1634/theoncologist.2015-0464

SAFE-HEaRt:一项在左心室功能降低的HER2阳性乳腺癌患者中评价HER2靶向治疗的心脏安全性的初步研究 - 原理和设计
SAFE‐HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2‐Positive Breast Cancer and Reduced Left Ventricular Function
Filipa Lynce, Ana Barac, Ming T. Tan, Federico M. Asch, Karen L. Smith, Chau Dang, Claudine Isaacs, Sandra M. Swain
The Oncologist 2017; 22:518-525; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0412

Complete Metabolic Response on Interim 18F‐Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long‐Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
Suyun Chen, Nuhad K. Ibrahim, Yuanqing Yan, Stephen T. Wong, Hui Wang, Franklin C. Wong
The Oncologist 2017; 22:526-534; first published on April 4, 2017; doi:10.1634/theoncologist.2016-0334


Prognostic Nomograms Stratify Survival of Patients with Hepatocellular Carcinoma Without Portal Vein Tumor Thrombosis After Curative Resection
Yi‐Peng Fu, Yong Yi, Jin‐Long Huang, Chu‐Yu Jing, Jian Sun, Xiao‐Chun Ni, Zhu‐Feng Lu, Ya Cao, Jian Zhou, Jia Fan, Shuang‐Jian Qiu
The Oncologist 2017; 22:561-569; first published on April 24, 2017; doi:10.1634/theoncologist.2016-0231

Volume 22, Number 4, April 2017

Clinical Trial Results

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
Rocío García‐Carbonero, Eric van Cutsem, Fernando Rivera, Jacek Jassem, Ira Gore, Jr, Niall Tebbutt, Fadi Braiteh, Guillem Argiles, Zev A. Wainberg, Roel Funke, Maria Anderson, Bruce McCall, Mark Stroh, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Herbert Hurwitz
The Oncologist 2017; 22:375-e30; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0133

Phase I Dose‐Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors
Jennifer Wheler, David Mutch, Joanne Lager, Christelle Castell, Li Liu, Jason Jiang, Anne M. Traynor
TThe Oncologist 2017; 22:377-e37; first published on March 8, 2017; doi:10.1634/theoncologist.2016-0257

Breast Cancer

Performance of Mid‐Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype
Rosalind P. Candelaria, Roland L. Bassett, William Fraser Symmans, Maheshwari Ramineni, Stacy L. Moulder, Henry M. Kuerer, Alastair M. Thompson, Wei Tse Yang
The Oncologist 2017; 22:394-401; first published on March 17, 2017; doi:10.1634/theoncologist.2016-0307

Health Outcomes and Economics of Cancer Care

Escalating Health Care Expenditures in Cancer Decedents' Last Year of Life: A Decade of Evidence from a Retrospective Population‐Based Cohort Study in Taiwan
Yen‐Ni Hung, Tsang‐Wu Liu, Fur‐Hsing Wen, Wen‐Chi Chou, Siew Tzuh Tang
The Oncologist 2017; 22:460-469; first published on February 23, 2017; doi:10.1634/theoncologist.2016-0283

No front page content has been created yet.


The Oncologist and the Society for Translational Oncology (STO) partner with the Chinese Society of Clinical Oncology (中国抗癌协会临床肿瘤学协作专业委员会, CSCO) and the CSCO Foundation (中国临床肿瘤学会基金会) on educational initiatives that address critical health and cancer care issues in China. These efforts serve to foster communication between Chinese physicians and other leaders in oncology practice throughout the world.